AGM
Présentation
Yann Duchesne
David Caumartin
David Auregan
Paris - 30 juin 2022
Déroulé de l'Assemblée Générale Mixte
Malakoff, le 30 juin 2022
- Ouverture de l'assemblée par le Président
- Constitution du bureau
- Président Yann Duchesne
- Scrutateurs David Auregan & David Caumartin
- Secrétaire David Auregan
- Annonce du quorum AGO&AGE 9 428 770 voix soit 39,505% / Dépôts des documents sur le bureau
- Présentation de l'activité au cours de l'exercice clos le 31 décembre
2021 - Présentation des comptes de l'exercice clos le 31 décembre 2021
- Présentation des rapports du commissaire aux comptes
- Présentation par le Secrétaire des résolutions
- Clôture de l'assemblée
2 | © 2021 Theraclion | 28.06.2022 |
Management
Présentation de l'activité 2022
David Caumartin
Paris - Juin 2022
THERACLION'S LEADERSHIP TEAM
Yann Duchesne
Executive Chairman
-
Former Managing Partner of McKinsey
France - Senior Partner in private equity fund
Doughty Hanson - Group CEO of industrial and commercial conglomerate IBL Group
-
Chairman of pharmaceutical group
Medis - Founding shareholder of California- based biotechnology company Phylex
David Caumartin
Chief Executive Officer
- CEO of Theraclion since 2014
- 14 years at GE Healthcare:
- Sales
- Marketing
- Product Development
- Computed Tomography and Radiology (8yr) o Global Mammography Activity Director (4yr)
- VP Strategy in Mergers & Acquisitions at Alstom Thermal Power (2012-2014)
- France Biotech Vice President since 2018
THERACLION
102, rue Etienne Dolet 92240 Malakoff
T +33 1 55 48 90 70
- contact@theraclion.com
Finance:
david.auregan@theraclion.com
Marketing:
anja.kleber@theraclion.com
April 2022
HIGH INTENSITY FOCUSED ULTRASOUND (HIFU)
A Technology & Theraclion achievements
Technology
Spherical transducer
Concentrate at the focal
point
Variable depth
Adjustable focus
Theraclion's improvements
Focused acoustic wave
through the tissue with an effect at
the focal point
Localized tissue
heating (85°C)
Wide range of bioeffects
4 Principle of action
Non-thermalThermal ablation
Theraclion's R&D
Hyper-thermia Histotripsy
29 Biological effects
Image guided | Target to be treated | Cooling disposable |
therapy | ||
As small as 1x1.5mm or | device | |
Ultrasound vision | ||
as large as 10x16mm | To control skin effects | |
co-registered on the target | ||
including
Vascular occlusion | Vaso-constriction | |
Tissue destruction
5 | © 2022 Theraclion | June 22 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Theraclion SA published this content on 30 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 June 2022 15:52:07 UTC.